X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (889) 889
Publication (115) 115
Book Review (10) 10
Book Chapter (2) 2
Conference Proceeding (2) 2
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (585) 585
sphingosine - analogs & derivatives (579) 579
fingolimod hydrochloride (574) 574
humans (552) 552
animals (465) 465
male (369) 369
multiple sclerosis (354) 354
fty720 (333) 333
female (330) 330
fingolimod (304) 304
immunosuppressive agents - therapeutic use (300) 300
propylene glycols - therapeutic use (260) 260
mice (257) 257
propylene glycols - pharmacology (233) 233
immunosuppressive agents - administration & dosage (224) 224
sphingosine - therapeutic use (210) 210
immunosuppressive agents - pharmacology (205) 205
propylene glycols - administration & dosage (204) 204
adult (200) 200
multiple sclerosis - drug therapy (184) 184
multiple sclerosis, relapsing-remitting - drug therapy (183) 183
oral fingolimod (183) 183
sphingosine - pharmacology (183) 183
rats (174) 174
clinical neurology (172) 172
sphingosine - administration & dosage (170) 170
immunology (169) 169
immunosuppressive agents - adverse effects (163) 163
middle aged (152) 152
pharmacology & pharmacy (152) 152
administration, oral (138) 138
fingolimod hydrochloride - therapeutic use (138) 138
sphingosine 1-phosphate (131) 131
neurosciences (128) 128
mice, inbred c57bl (124) 124
treatment outcome (121) 121
disease models, animal (115) 115
fingolimod hydrochloride - administration & dosage (114) 114
transplantation (109) 109
propylene glycols - adverse effects (107) 107
sphingosine-1-phosphate (102) 102
fingolimod hydrochloride - pharmacology (101) 101
sphingosine - adverse effects (101) 101
drug therapy (100) 100
neurology (98) 98
research (93) 93
sphingosine (92) 92
analysis (91) 91
lymphocytes (88) 88
receptors, lysosphingolipid - metabolism (88) 88
time factors (88) 88
fingolimod hydrochloride - adverse effects (86) 86
natalizumab (85) 85
multiple-sclerosis (82) 82
immunosuppressant (81) 81
dosage and administration (78) 78
surgery (75) 75
apoptosis (74) 74
dose-response relationship, drug (74) 74
relapsing multiple-sclerosis (72) 72
experimental autoimmune encephalomyelitis (71) 71
phosphates (70) 70
young adult (67) 67
care and treatment (66) 66
interferon (66) 66
in-vivo (65) 65
placebo-controlled trial (65) 65
hemic and lymphatic diseases (64) 64
inflammation (64) 64
article (62) 62
magnetic resonance imaging (61) 61
central-nervous-system (60) 60
circulating mature lymphocytes (59) 59
receptors, lysosphingolipid - agonists (59) 59
t-cells (58) 58
apoptosis - drug effects (57) 57
abridged index medicus (56) 56
lymphocyte egress (56) 56
research article (56) 56
disease progression (55) 55
health aspects (54) 54
t-lymphocytes - drug effects (54) 54
lymphocytes - drug effects (53) 53
double-blind (52) 52
recurrence (52) 52
safety (52) 52
rodents (51) 51
graft survival - drug effects (49) 49
lymphocyte count (49) 49
medicine, general & internal (48) 48
therapy (48) 48
mice, inbred balb c (47) 47
sphingosine - metabolism (47) 47
t-lymphocytes - immunology (46) 46
expression (44) 44
medicine (44) 44
medicine, research & experimental (44) 44
patients (44) 44
adolescent (43) 43
multidisciplinary sciences (43) 43
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (855) 855
Japanese (11) 11
German (8) 8
Spanish (7) 7
Hungarian (6) 6
Chinese (2) 2
Russian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Drugs, ISSN 0012-6667, 10/2017, Volume 77, Issue 16, pp. 1755 - 1768
Since the approval of fingolimod, several selective sphingosine-1-phosphate receptor modulators have entered clinical development for multiple sclerosis.... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | LONG-TERM | BAF312 SIPONIMOD | TUMEFACTIVE MS | ORAL FINGOLIMOD FTY720 | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | OPEN-LABEL | TOXICOLOGY | PLACEBO-CONTROLLED TRIAL | DISEASE-MODIFYING THERAPIES | SAFETY PROFILE | CLINICAL-PRACTICE | Fingolimod Hydrochloride - pharmacology | Multiple Sclerosis - diagnosis | Risk Assessment | Humans | Natalizumab - adverse effects | Natalizumab - chemistry | Natalizumab - pharmacology | Fingolimod Hydrochloride - chemistry | Natalizumab - administration & dosage | Multiple Sclerosis - immunology | Immunosuppressive Agents - adverse effects | Receptors, Lysosphingolipid - metabolism | Fingolimod Hydrochloride - adverse effects | Immunosuppressive Agents - pharmacology | Immunosuppressive Agents - administration & dosage | Immunosuppressive Agents - chemistry | Fingolimod Hydrochloride - administration & dosage | Multiple Sclerosis - drug therapy | Multiple sclerosis | Care and treatment | Usage | Dosage and administration | Fingolimod | Drug therapy | Short term | Phosphates | Washouts | Nervous system | Malignancy | Modulators | Sphingosine 1-phosphate | Cell adhesion & migration | Lymphocytes | Phosphate | Risk assessment | Safety | Patient satisfaction | Heart diseases | Drug dosages | Edema | Lymphatic system | Effectiveness | Immunomodulation | Switching | Studies | Heart rate | Side effects | Titration | Review
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 11/2016, Volume 59, Issue 21, pp. 9837 - 9854
Journal Article
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2015, Volume 10, Issue 4, p. e0124923
Journal Article
Pharmacological Research, ISSN 1043-6618, 06/2017, Volume 120, pp. 279 - 293
Multiple Sclerosis (MS) is a chronic pathology affecting the Central Nervous System characterized by inflammatory processes that lead to demyelination and... 
Teriflunomide | Immunogenetics | Multiple sclerosis | Fingolimod | Dimethyl fumarate | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | DE-NOVO SYNTHESIS | PLACEBO-CONTROLLED PHASE-3 | ADVERSE DRUG-REACTIONS | FUMARIC-ACID ESTERS | SPHINGOSINE 1-PHOSPHATE RECEPTOR-1 | PHARMACOLOGY & PHARMACY | DISEASE-MODIFYING THERAPIES | NF-KAPPA-B | STEVENS-JOHNSON-SYNDROME | SIGNAL-REGULATED KINASE | Toluidines - therapeutic use | Administration, Oral | Humans | Immunosuppressive Agents - therapeutic use | Multiple Sclerosis - genetics | Toluidines - adverse effects | Toluidines - administration & dosage | Crotonates - therapeutic use | Animals | Dimethyl Fumarate - therapeutic use | Dimethyl Fumarate - adverse effects | Multiple Sclerosis - immunology | Immunosuppressive Agents - adverse effects | Crotonates - administration & dosage | Crotonates - adverse effects | Dimethyl Fumarate - administration & dosage | Fingolimod Hydrochloride - adverse effects | Fingolimod Hydrochloride - therapeutic use | Immunosuppressive Agents - administration & dosage | Fingolimod Hydrochloride - administration & dosage | Multiple Sclerosis - drug therapy | Drug therapy | Medical research | Pharmacogenetics | Histocompatibility antigens | HLA histocompatibility antigens | Medicine, Experimental | Development and progression | Interferon | Oral medication | Drug approval
Journal Article